Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Colorectal Disease
Published in: International Journal of Colorectal Disease 5/2007

01-05-2007 | Review

Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review

Authors: Gunther Klautke, Rainer Fietkau

Published in: International Journal of Colorectal Disease | Issue 5/2007

Login to get access

Abstract

Background

The rate of local recurrence of locally advanced rectal cancer (stage III and IV according to the criteria of Union Internationale Contre Le Cancer) is still high, and also the rate of distant metastases. There are a lot of phase I/II trails of intensified neoadjuvant radiochemotherapy with different chemotherapeutic agents and current protocols to radiotherapy.

Aim

The objective of this review of literature was to evaluate the necessity, the results, and comparability of the different regimes and to evaluate a potential impact on later adjuvant chemotherapy.
Literature
1.
Douglass HO Jr, Moertel CG, Mayer RJ, Thomas PR, Lindblad AS, Mittleman A, Stablein DM, Bruckner HW (1986) Survival after postoperative combination treatment of rectal cancer. N Engl J Med 315:1294–1295PubMedCrossRef
2.
Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA (1991) Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324:709–715PubMedCrossRef
3.
Tepper JE, O’Connell MJ, Petroni GR, Hollis D, Cooke E, Benson AB 3rd, Cummings B, Gunderson LL, Macdonald JS, Martenson JA (1997) Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol 15:2030–2039PubMed
4.
Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRef
5.
O’Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502–507PubMedCrossRef
6.
Yoon WH, Choi JH, Kim JR, Kim TD, Lim K, Hwang BD, Song KS, Jang JY, Kim JS, Kim MJ, Cho MJ (2001) Enhanced tumoricidal effect of preoperative chemoradiation using capecitabine for locally advanced rectal cancer. Proc Am Soc Clin Oncol 20 (abstract 2165)
7.
Calvo FA, Gomez-Espi M, Diaz-Gonzalez JA, Cantalapiedra R, Marcos P, Garcia Alfonso P, Herranz R, Alvarez E (2001) Pathologic downstaging of T3-4Nx rectal cancer after chemoradiation: 5-fluorouracil vs. tegafur. Int J Radiat Oncol Biol Phys 51:1264–1270PubMedCrossRef
8.
Videtic G, Fisher B, Perera F, Bauman GS, Kocha WI, Taylor M Vincent MD, Plewes EA, Engel CJ, Stitt LW (1998) Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer. Int J Radiat Oncol Biol Phys 42:319–324PubMedCrossRef
9.
Ronzoni M, Ceresoli GL, Zucchinelli P, Cozzarini C, Villa E (2001) Preoperative neoadjuvant radio-chemotherapy for T3–T4 rectal cancer. Proc Am Soc Clin Oncol 20 (abstract 2245)
10.
Coquard R, Martin P, Ardiet JM, Lledo G, Velay B, Martin JP, Ardisson P, Napoleon B, Pujol B (2001) Preoperative chemoradiation in T3T4 rectal cancer: better pathological response and downstaging with infusional 5FU than with 5FU/leucovorin. A comparative study. Proc Am Soc Clin Oncol 20 (abstract 2240)
11.
Dunst J, Reese T, Sutter T, Zuhlke H, Hinke A, Kolling-Schlebusch K, Frings S (2002) Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 20:1005–1009CrossRef
12.
Ngan SY, Michael M, Mackay J, McKendrick J, Leong T, Lim Joon D, Zalcberg JR (2004) A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br J Cancer 91:1019–1024PubMed
13.
Aschele C, Friso ML, Pucciarelli S, Lonardi S, Sartor L, Fabris G, Urso ED, Del Bianco P, Sotti G, Lise M, Monfardini S (2005) A phase I–II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol 16:1140–1146PubMedCrossRef
14.
Glynne-Jones R, Sebag-Montefiore D, Maughan TS, Falk SJ, McDonald AC (2006) A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation in patients with locally advanced rectal cancer. Ann Oncol 17:50–56PubMedCrossRef
15.
Loi S, Ngan SY, Hicks RJ, Mukesh B, Mitchell P, Michael M, Zalcberg J, Leong T, Lim-Joon D, Mackay J, Rischin D (2005) Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial. Br J Cancer 92:655–661PubMedCrossRef
16.
Sebag-Montefiore D, Glynne-Jones R, Falk S, Meadows HM, Maughan T (2005) A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group study. Br J Cancer 93:993–998PubMedCrossRef
17.
Machiels JP, Duck L, Honhon B, Coster B, Coche JC, Scalliet P, Humblet Y, Aydin S, Kerger J, Remouchamps V, Canon JL, Van Maele P, Gilbeau L, Laurent S, Kirkove C, Octave-Prignot M, Baurain JE, Kartheuser A, Sempoux C (2005) Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 16:1898–1905PubMedCrossRef
18.
Rubbia-Brandt L, Audard V, Sartoretti P, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G, Terris B (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460–466PubMedCrossRef
19.
Trisolini R, Lazzari Agli L, Tassinari D, Rondelli D, Cancellieri A, Patelli M, Falcone F, Poletti V (2001) Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy. Eur Respir J 18:243–245PubMed
20.
Yague XH, Soy E, Merino BQ, Puig J, Fabregat MB, Colomer R (2005) Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. Clin Transl Oncol 7:515–517PubMed
21.
Rödel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R (2003) Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21:3098–3104PubMedCrossRef
22.
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914PubMedCrossRef
23.
Mehta VK, Cho C, Ford JM, Jambalos C, Poen J, Koong A, Lin A, Bastidas JA, Young H, Dunphy EP, Fisher G (2003) Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Int J Radiat Oncol Biol Phys 55:132–137PubMedCrossRef
24.
Hofheinz R, von Gerstenberg-Helldorf B, Wenz F, Gnad U, Kraus-Tiefenbacher U, Muldner A, Hehlmann R, Post S, Hochhaus A, Willeke F (2005) Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 23:1350–1357PubMedCrossRef
25.
Klautke G, Küchenmeister U, Foitzik T, Ludwig K, Klar E, Fietkau R (2006) Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study. Br J Cancer 94:976–981PubMedCrossRef
26.
Klautke G, Ludwig K, Klar E, Freund M, Fietkau R (2006) Toxicity and efficasy of four schedules of intensified neoadjuvant chemoradiotherapy with irinotecan and 5-Fu or Capecitabine in patients with locally advanced rectal cancer. J Clin Oncol 24 (abstract 13550)
27.
Klautke G, Feyerherd P, Ludwig K, Prall F, Foitzik T, Fietkau R (2005) Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer. Br J Cancer 92:1190–1197CrossRef
28.
Gollins SW, Myint S, Levine E, Morris J, Haylock B, Susnerwala S, Saunders M, Biswas A (2005) Phase I study of radiotherapy (RT) plus concurrent irinotecan (CPT-11) and capecitabine (CAP) as preoperative downstaging treatment for locally advanced inoperable rectal cancer. J Clin Oncol 23 (abstract 3565)
29.
Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65PubMedCrossRef
30.
Sappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J, Kabbinavar F, Novotny W, Sarkar S, Hurwitz H (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91:173–180CrossRef
31.
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–147PubMedCrossRef
32.
Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pister PW, Charnsangavej C, Delclos ME, O’Reilly M, Lee JE, Wolff RA (2006) Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24:1145–1151PubMedCrossRef
33.
Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey JN, Lynch P, Ellis LM, Wolff R, Lenzi R, Abbruzzese J, Pazdur R, Hoff PM, Allen P, Brown T, Skibber J (2001) Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 24:107–112PubMedCrossRef
34.
Rödel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8696PubMedCrossRef
35.
Losi L, Luppi G, Gavioli M, Iachetta F, Bertolini F, D’Amico R, Jovic G, Bertoni F, Falchi AM, Conte PF (2005) Prognostic value of Dworak grade regression in patients with rectal carcinoma treated with preoperative radiochemotherapy. Int J Colorectal Dis (Epub ahead of print)
36.
Vironen J, Juhola M, Kairaluoma M, Jantunen I, Kellokumpu I (2005) Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma. Int J Colorectal Dis 20:440–445PubMedCrossRef
37.
Fietkau R, Barten M, Klautke G, Klar E, Ludwig K, Thomas H, Brinckmann W, Friedrich A, Prall F, Hartung G, Küchenmeister U, Kundt G (2006) Postoperative chemotherapy may not be necessary for patients with ypN0-category following neoadjuvant chemoradiotherapy of rectal cancer. Colorectal Dis 49:1–9
38.
Hartley A, Ho KF, McConkey C, Geh JL (2005) Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. Br J Radiol 78:934–938PubMedCrossRef
39.
Wiltshire KL, Ward IG, Swallow C, Oza AM, Cummings B, Pond GR, Catton P, Kim J, Ringash J, Wong CS, Wong R, Siu LL, Moore M, Brierley J (2006) Preoperative radiation with concurrent chemotherapy for resectable rectal cancer:effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. Int J Radiat Oncol Biol Phys 64:709–716PubMedCrossRef
40.
Chapet O, Romestaing P, Souquet JC, Favrel V, Ardiet JM, d’Hombres A, Gerard JP (2005) Preoperative radiotherapy for rectal adenocarcinoma. Which are strong prognostic factors ? Int J Radiat Oncol Biol Phys 61:1371–1377PubMedCrossRef
41.
Klautke G, Ludwig K, Foitzik T, Klar E, Fietkau R (2005) Neoadjuvante irinotecanhaltige Radiochemotherapie bei Patienten mit lokal fortgeschrittenem Rektumkarzinom: Ergebnisse und Risikofaktoren. Strahlenther Onkol 181(Sonderband 1):56
42.
Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, Tebbutt N, Hill M, Ross PJ, Massey A, Oates J (2006) Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 24:668–674PubMedCrossRef
43.
Hille A, Christiansen H, Pradier O, Hermann RM, Siekmeyer B, Weiss E, Hilgers R, Hess CF, Schmidberger H (2005) Effect of pentoxifylline and tocopherol on radiation proctitis/enteritis. Strahlenther Onkol 181:606–614PubMedCrossRef
44.
Muller AC, Pigorsch S, Beyer C, Lautenschlager C, Dunst J (2005) Radioprotective effects of amifostine in vitro and in vivo measured with comet assay. Strahlenther Onkol 180:517–525
45.
Gerard JP, Chapet O, Nemoz C, Romestaing P, Mornex F, Coquard R, Barbet N, Atlan D, Adeleine P, Freyer G (2003) Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol 21:1119–1124PubMedCrossRef
46.
Turitto G, Panelli G, Frattolillo A, Auriemma A, de Luna FS, Cione G, De Angelis CP, Muto P, Iaffaioli RV (2006) Phase II study of neoadjuvant concurrent chemoradiotherapy with oxaliplatin-containing regimen in locally advanced rectal cancer. Front Biosci 11:1275–1279PubMedCrossRef
47.
Mitchell EP, Anne P, Fry R, Ahmad N, Boman B, Edmunston T, Rakinic S, Goldstein S, Rose L, Palazzo J, Cagir B, Kovatich A, Hauck W, Fishel R, Bonanni R, Hoey D, Rose D, Curran W (2001) Combined mortality therapy of locally advanced or recurrent adenocarcinoma of the rectum: report of a phase I trail of chemotherapy with CPT-11, 5-FU and concomitant irradiation. Proc Am Soc Clin Oncol 20 (abstract 519)
48.
Alonso V, Salud A, Escudero P, Bueso P, Mira M, Valencia J, Polo S, Ruiz de Lobera A, Lao J, Lastra R (2005) Phase II trial of preoperative chemoradiotherapy with irinotecan and infusional 5-fluorouracil in locally advanced operable rectal carcinoma. J Clin Oncol 23 (abstract 3542)
49.
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–147PubMedCrossRef
50.
Machiels JP, Sempoux C, Scalliet P, Coche JC, Coster B, Canon JL, Kerger J, Van Cutsem E, Peeters M, Haustermans K (2006) Phase I study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. J Clin Oncol 24 (abstract 3552)
51.
Chung KY, Minsky B, Schrag D, O’Reilly E, D’Adamo D, Hollywood E, Quinones M, Saltz L (2006) Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. J Clin Oncol 24 (abstract 3560)
52.
Arnold D, Hipp M, Reese T, Hohenberger W, Liersch T, Lordick F, Sülberg H, Sauer R, Rödel C (2006) Phase I/II study of cetuximab, capecitabine and oxaliplatin (CAPOX) combined With standard radiotherapy (RTX) as neoadjuvant treatment of advanced rectal Cancer (RC). J Clin Oncol 24 (abstract 3574)
Metadata
Title
Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review
Authors
Gunther Klautke
Rainer Fietkau
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
International Journal of Colorectal Disease / Issue 5/2007
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-006-0204-8

Other articles of this Issue 5/2007

International Journal of Colorectal Disease 5/2007 Go to the issue

Original Article

HER-2/neu overexpression is an independent prognostic factor in colorectal cancer

Letter to the Editor

Non-iatrogenic perforation of the colon due to acute barotrauma

Case Report

Malignant fibrous histiocytoma of the sigmoid: a case report and review of the literature

Original Article

Different matrix micro-environments in colon cancer and diverticular disease

Original Article

p53 protein accumulation as a prognostic marker in sporadic colorectal cancer

Case Report

Hematological malignancies in chronic inflammatory bowel diseases: report of five cases and review of the literature